MuScreen™

Syngeneic and tumor homograft *in vivo* immunotherapy screening

CrownBio
CONNECTING SCIENCE TO PATIENTS

Rapidly progress your immuno-oncology drug development programs with our highly experienced screening platform.

Choose MuScreen to:

- Screen agents using well-characterized syngeneic and tumor homograft models, with ICI benchmarking, baseline tumor immune profile, and tumor RNAseq data available.

- Evaluate single or combination agent strategies.

- Efficiently identify responder models.

- Uncover mechanism of action and predictive biomarkers.

- Benefit from CrownBio covering the cost of the vehicle group for all models.

Syngeneic Model Panels

Choose our well-characterized syngeneic model panels, displaying heterogeneous immune phenotypes, for rapid and large scale compound efficacy or PD evaluation.

Tumor Homograft Panel

Choose our unique tumor homograft models featuring clinically relevant mutations, for single agent immunotherapy and combination I/O and targeted agent efficacy assessment.

Our unique MuPrime™ tumor homografts are transplants of spontaneous or carcinogen-induced GEMM tumors in immunocompetent syngeneic hosts:

- Carrying disease-relevant oncogenic mutations of human cancers including KRAS, PTEN, and TP53.

- Preserving original GEMM tumor histo- and molecular pathology.

Tumor Growth Inhibition (TGI)

FACS Analysis
Total T, CD4$^+$, CD8$^+$ T, T$_{reg}$, NK, MDSC, Macrophage

Contact Sales
US: +1.855.827.6968
UK: +44 (0)870 166 6234
busdev@crownbio.com

Schedule Scientific Consultation
Request a consultation to discuss your project.
consultation@crownbio.com

Explore Scientific Data
Log into MuBase®
to review model data.
mubase.crownbio.com

Version 1.0

+1.855.827.6968 | busdev@crownbio.com | www.crownbio.com